Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid ( sUA ). Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. Xanthine oxidase inhibitors ( XOI s) are the mainstay of chronic gout treatment, with generic allopurinol prescribed much more extensively than the brands Uloric and Zurampic. Gout Treatment Algorithms presents urate-lowering therapy prescribing patterns and provides insights into the uptake of novel branded agents against the background of generic allopurinol dominance.

Questions Answered in This Report:

    • What patient share do key therapies and brands garner by line of therapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed gout patients? 
    • How has Zurampic been integrated into the treatment algorithm? 
    • What proportion of gout patients receive drug therapy within one year of diagnosis, and how quickly? 
    • What percentage of patients progress to later lines of therapy within one year of diagnosis? 
    • What percentage of gout patients are treated with monotherapy versus combination therapy? 
    • What are the most widely used combination therapies? 
    • What are the product-level compliance and persistency rates among drug-treated patients with gout?